Scientific Presentations
Mechanism of Action of Posiphen: from Model to Human
Speaker: Maria L. Maccecchini
Presentation, January 2011. WCBR,
More >>>>>
Posiphen Human Biomarker Data
H.W. Holloway, N.H. Greig, V. John, C. Pan, M. Murphy, MY Chang, M.L. Maccecchini
Poster, January 2011. WCBR,
More >>>>>
Targeting Alzheimer's and Other Neurodegenerative Diseases via a Novel Mechanism of Action
Speaker: Maria L. Maccecchini
Presentation, November 30, 2010. CNDR Talk: University of Pennsylvania,
More >>>>>
Posiphen® Technical Summary
Presentation, July 23, 2010.
More >>>>>
Posiphen Human Clinical Data
Maria L. Maccecchini, M. Murphy, N. Skuban, Debomoy K. Lahiri, Nigel H. Greig
Poster, July 2010. ICAD,
More >>>>>
Targeting Alzheimer's with Novel Therapuetics
Speaker: Maria L. Maccecchini
Presentation, May 11, 2010. Neuroscience Network,
More >>>>>
Traumatic Brain Injury Increases Susceptibility to Alzheimer's Disease
Speaker: Maria L. Maccecchini
November 17, 2009. Biotech 2009,
More >>>>>
ICAD Posiphen
Poster, June 30, 2009. ICAD,
More >>>>>
WCBR Posiphen® Poster
Poster, June 2009. WCBR,
More >>>>>
Pathways leading to Alzheimer's Disease
Speaker: Maria L. Maccecchini
June 2009. World Pharma Congress on Alzheimer's Disease,
More >>>>>
Interrelatedness of Alzheimer Pathways
Speaker: Maria L. Maccecchini
Presentation, June 2009. World Pharma Congress,
More >>>>>
Posiphen® and Analogs: Experimental Alzheimer agents that reduce amyloid-ß peptide by lowering amyloid precursor protein levels in culture and in vivo
Harold W. Holloway¹, Donald K. Ingram², Maria L. Maccecchini³, Nigel H. Greig¹
Poster, January 2009. Winter Conference on Brain Research,
More >>>>>
The Michael J. Fox Foundation for Parkinson's Research: Therapeutics Development Initiative
Presentation, June 2008.
More >>>>>
Posiphen® Treatment is Able to Reduce APP Levels in Ta65Dn Mouse Model of Down Syndrome
Poster, 2008. ICAD,
More >>>>>
Oral Posiphen® Treatment Lowers Aß42 in Mouse Brain
Poster, July 2006. ICAD,
More >>>>>
